Mechanism of Action for Agents Used to Treat Pediatric Atopic Dermatitis
Joshua Zeichner, MD, and Raj Chovatiya, MD, PhD, dive deep into the pathogenesis of atopic dermatitis and discuss how agents treating atopic dermatitis work.
Characteristics of Type 2 Inflammation and the Impact of Itch
Joshua Zeichner, MD, and Vikash Oza, MD, discuss characteristics of type 2 inflammation and the impact of itching on pediatric patients with atopic dermatitis.
How Ruxolitinib Will Change the Future of Vitiligo Treatment
July 21st 2022Pearl Grimes, MD, FAAD, and director of the Grimes Center of Medical and Aesthetic Dermatology and the Vitiligo & Pigmentation Institute of Southern California in Los Angeles, explains why the FDA approval of ruxolitinib cream 1.5% is monumental in the treatment of vitiligo.